AVECRIS
AVECRIS is a Singapore-based biotech developing SPRING DNA™, a rationally designed non-viral gene delivery platform offering sustained, redosable, cell-type specific expression for gene therapy and genetic medicines. It serves pharmaceutical partners, research institutions, and government agencies via licensing, co-development, and direct research product sales.
- Company typePrivate
- Founded2017
- HeadquartersSingapore, Singapore
- Headcount1–10
- GTM typeB2B
- OfferingServices
What AVECRIS does
AVECRIS is a Singapore-based, privately-held biotechnology company founded in 2017 that develops SPRING DNA™, a non-viral gene delivery platform technology originally invented by researchers at the National University of Singapore. The platform uses a rationally designed universal DNA construct with unique spring-like loop ends that enable exonuclease resistance, sustained expression, cell-type specific targeting via an on/off switch, redosability, immune-quiet behavior, non-integrating delivery, and accommodation of gene cargo of any size. AVECRIS positions SPRING DNA as a programmable alternative to viral vectors and RNA-based modalities (including mRNA, circular RNA, and self-amplifying RNA) for gene therapy, genetic vaccination, gene editing, and diagnostics across multiple therapeutic areas including genetic diseases, metabolic diseases, hematology, oncology, women's health, immunology, gastroenterology, ophthalmology, and dermatology.
The company's business model combines two revenue streams: direct product sales of SPRING DNA vectors for research and evaluation use (a 1 mg SPRING DNA research SKU is sold at $25,000 through an e-commerce storefront), and technology licensing and co-development arrangements with pharmaceutical, biotechnology, and government partners. The go-to-market motion is enterprise-led, anchored by strategic partnerships such as the inaugural Cystic Fibrosis Foundation Golden Ticket Award (July 2022) and BARDA's inaugural accelerator cohort and Health Security Industry Day spotlight (2022). The platform is supported by a comprehensive IP portfolio and a leadership team comprising CEO Pablo Cagnoni, CSO Volker Patzel, Co-founder and Managing Director Dennis Mak, Director of R&D Sushmita Poddar, and additional co-founders, directors, and scientific advisors with deep domain expertise in non-viral gene delivery and bioprocess manufacturing.
AVECRIS firmographics
Firmographics- Name
- AVECRIS
- Legal name
- Avecris
- Website
- https://avecris.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- AVECRIS is a Singapore-based biotech developing SPRING DNA™, a rationally designed non-viral gene delivery platform offering sustained, redosable, cell-type specific expression for gene therapy and genetic medicines. It serves pharmaceutical partners, research institutions, and government agencies via licensing, co-development, and direct research product sales.
- Ownership category
- akta.pro rank
AVECRIS industry classification
Industry- Product category
- Gene Therapy Platform Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
Keywords
Where AVECRIS is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Markets served
AVECRIS business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- SPRING DNA Product Sales: Direct sales of SPRING DNA vectors for research and evaluation purposes. The company sells SPRING DNA vectors encoding reporter genes and promoters for laboratory use, with products like 1 mg SPRING DNA available at $25,000 per unit.
- Technology Licensing and Co-development: Licensing of SPRING DNA platform technology to pharmaceutical and biotechnology partners for therapeutic development across multiple disease areas. Partnerships with organizations like BARDA and Cystic Fibrosis Foundation suggest government and foundation funding for co-development.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | 1 mg SPRING DNA for Evaluation Use |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
AVECRIS product offering
Product offeringCore offering
AVECRIS develops and commercializes SPRING DNA™, a proprietary non-viral gene delivery platform technology invented at the National University of Singapore. The platform enables sustained, precise, cell-type specific gene expression through a unique spring-like loop structure, with applications in gene therapy, genetic vaccination, gene editing, and diagnostics across multiple therapeutic areas. The company sells SPRING DNA vectors directly for research/evaluation use and licenses the platform to biopharmaceutical partners for therapeutic development.
Product overview
AVECRIS operates as a SPRING DNA™ platform company developing a new class of programmable genetic medicines. The core offering is the SPRING DNA™ technology platform, which enables non-viral DNA delivery with sustained, precise, cell-type specific gene expression. The platform is complemented by SPRING DNA research products (such as 1 mg SPRING DNA vectors) sold for evaluation use. The company is developing medicines across multiple therapeutic areas including genetic diseases, metabolic diseases, hematology, oncology, women's health, immunology, gastroenterology, ophthalmology, and dermatology, targeting applications in gene therapy, genetic vaccination, gene editing, and diagnostics.
Differentiator
Problem solved
Functional benefit
Brands
- SPRING DNA: A proprietary, minimalistic gene construct platform technology for non-viral DNA delivery with features including sustained expression, precise cell-type specific targeting, redosability, immune quiet properties, non-integrating mechanism, and ability to carry genes of any size.
- SPRING Science
Products and services
- SPRING DNA Platform A proprietary, programmable non-viral gene delivery platform technology that enables sustained, precise, cell-type specific gene expression. Licensed to biopharmaceutical companies for developing genetic medicines across multiple therapeutic areas including genetic diseases, oncology, rare diseases, metabolic diseases, hematology, immunology, ophthalmology, and dermatology.
- 1 mg SPRING DNA Research Vector SPRING DNA vector encoding reporter gene and promoter sold in 1 mg quantities at $25,000 per unit for evaluation and laboratory research use by research institutions and biopharmaceutical companies.
Quantifiable outcome
- Single-day production and purification capability
- +1 more outcomes
Companies that use AVECRIS
Customer profileSegments3 records
Ideal customer profiles2 records
AVECRIS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
AVECRIS partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- U.S. Department of Health and Human Services / BARDAcoreBARDA selected AVECRIS to spotlight at the 2022 BARDA Health Security Industry Day, recognizing the company's innovative biotechnology with applications in health security and pandemic preparedness. BARDA also selected AVECRIS for its inaugural accelerator cohort to develop innovative biomanufacturing capabilities.
- Cystic Fibrosis FoundationcoreThe Cystic Fibrosis Foundation awarded AVECRIS with the first ever Golden Ticket Award specifically designed to advance novel non-viral platform technology. This award recognizes innovative approaches to treating cystic fibrosis through genetic medicine.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
AVECRIS competitors and assessment
Company assessmentDirect peers
- Touchlight Genetics: UK-based developer of doggybone DNA (dbDNA), a minimal, synthetic, closed-ended DNA vector for gene therapy and cell therapy. Closest direct competitor to SPRING DNA, also competing on exonuclease resistance, scalability, and elimination of bacterial backbone sequences.
- Generation Bio: US-based non-viral gene therapy company developing DNA-based therapeutics delivered via lipid nanoparticles, targeting genetic diseases. Shares the non-viral DNA delivery approach and redosability positioning that SPRING DNA emphasizes.
- Quantoom Biosciences: Belgium-based developer of DNA and mRNA production technologies with a focus on cost-efficient, scalable, enzymatic manufacturing. Highly comparable to SPRING DNA's enzymatic, single-day manufacturing thesis.
Emerging players
- Tessera Therapeutics: US-based Flagship Pioneering company developing 'gene writing' — a programmable approach to DNA-based therapeutics. Competes conceptually in the non-viral DNA space with SPRING DNA, targeting similar genetic-disease indications.
- Strand Therapeutics: US-based developer of self-amplifying and programmable mRNA therapeutics with cell-type specific expression. Direct conceptual competitor to SPRING DNA's 'precise expression' positioning for next-generation genetic medicines.
- Verve Therapeutics: US-based in vivo gene-editing company using lipid nanoparticle delivery of base-editing payloads. Comparable as a non-viral, in vivo genetic-medicine developer pursuing similar cardiology and rare-disease opportunities.
Broad incumbents
- Aldevron: US-based (now part of Danaher) manufacturer of plasmid DNA, mRNA, and proteins used across gene therapy and cell therapy pipelines. Comparable as a supplier/competitor in DNA-based therapeutic manufacturing for the same customer base as AVECRIS.
- TriLink BioTechnologies: US-based (now part of Maravai LifeSciences) CDMO for mRNA, plasmid DNA, oligonucleotides, and nucleotides. Comparable as a nucleic-acid manufacturing competitor serving overlapping gene therapy customers.
- Moderna: mRNA platform incumbent with broad therapeutic and vaccine pipeline. Competes with SPRING DNA on the non-viral delivery frontier and explicitly on positioning that aims to displace traditional viral vectors.
- BioNTech: mRNA and gene therapy incumbent spanning infectious disease vaccines and oncology. Competes for the same partner pharma customers and therapeutic indications as SPRING DNA in the broader non-viral genetic-medicine space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
AVECRIS social profiles
Digital presenceAVECRIS financial estimates
Financial estimateRevenue estimate
Valuation estimate
AVECRIS leadership team
Management profileNumber of profiles
Profiles8 records
AVECRIS funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AVECRIS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AVECRIS
What does AVECRIS do?
AVECRIS develops and commercializes SPRING DNA™, a proprietary non-viral gene delivery platform technology invented at the National University of Singapore. The platform enables sustained, precise, cell-type specific gene expression through a unique spring-like loop structure, with applications in gene therapy, genetic vaccination, gene editing, and diagnostics across multiple therapeutic areas. The company sells SPRING DNA vectors directly for research/evaluation use and licenses the platform to biopharmaceutical partners for therapeutic development.
Is AVECRIS a public or private company?
AVECRIS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AVECRIS founded?
AVECRIS was founded in 2017. It employs 1 to 10 people.
Where is AVECRIS based?
AVECRIS is headquartered in Singapore, Singapore, in the Asia region.
How does AVECRIS make money?
Two revenue lines are on record. SPRING DNA Product Sales are the primary driver. The others are technology Licensing and Co-development.
Who are AVECRIS's main competitors?
Direct peers on record are Touchlight Genetics, Generation Bio and Quantoom Biosciences. Emerging players are Tessera Therapeutics, Strand Therapeutics and Verve Therapeutics. Broad incumbents are Aldevron, TriLink BioTechnologies, Moderna and BioNTech.
Does AVECRIS have an API?
No public API is recorded for AVECRIS.
What industry is AVECRIS in?
AVECRIS's product category is Gene Therapy Platform Technology. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714.